Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma
Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine. Transsphenoidal pituitary adenoma resection was done with normali...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-07-01
|
| Series: | Journal of Investigative Medicine High Impact Case Reports |
| Online Access: | https://doi.org/10.1177/23247096211029750 |
| _version_ | 1818652490084646912 |
|---|---|
| author | Lakshmi P. Menon MD Wedad Rahman MD |
| author_facet | Lakshmi P. Menon MD Wedad Rahman MD |
| author_sort | Lakshmi P. Menon MD |
| collection | DOAJ |
| description | Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine. Transsphenoidal pituitary adenoma resection was done with normalization of the prolactin level. Priapism is a rare side effect of dopamine agonists that warrants discontinuation of therapy. Patients should be educated about this potential side effect at the time of prescribing the medication. |
| first_indexed | 2024-12-17T02:22:50Z |
| format | Article |
| id | doaj.art-b789e19109394e04a708803487b2f8a8 |
| institution | Directory Open Access Journal |
| issn | 2324-7096 |
| language | English |
| last_indexed | 2024-12-17T02:22:50Z |
| publishDate | 2021-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Investigative Medicine High Impact Case Reports |
| spelling | doaj.art-b789e19109394e04a708803487b2f8a82022-12-21T22:07:13ZengSAGE PublishingJournal of Investigative Medicine High Impact Case Reports2324-70962021-07-01910.1177/23247096211029750Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With ProlactinomaLakshmi P. Menon MD0Wedad Rahman MD1University of Arkansas for Medical Sciences, Little Rock, AR, USAPiedmont Physicians Group Endocrinology, Atlanta, GA, USADopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine. Transsphenoidal pituitary adenoma resection was done with normalization of the prolactin level. Priapism is a rare side effect of dopamine agonists that warrants discontinuation of therapy. Patients should be educated about this potential side effect at the time of prescribing the medication.https://doi.org/10.1177/23247096211029750 |
| spellingShingle | Lakshmi P. Menon MD Wedad Rahman MD Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma Journal of Investigative Medicine High Impact Case Reports |
| title | Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma |
| title_full | Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma |
| title_fullStr | Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma |
| title_full_unstemmed | Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma |
| title_short | Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma |
| title_sort | recurrent priapism from cabergoline and bromocriptine in a hypogonadal man with prolactinoma |
| url | https://doi.org/10.1177/23247096211029750 |
| work_keys_str_mv | AT lakshmipmenonmd recurrentpriapismfromcabergolineandbromocriptineinahypogonadalmanwithprolactinoma AT wedadrahmanmd recurrentpriapismfromcabergolineandbromocriptineinahypogonadalmanwithprolactinoma |